BVB. O. Varynskyi

B. O. Varynskyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


B. O. Varynskyi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The research of pharmacokinetic parameters and metabolism of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4h-1,2,4-triazol-3-yl)thio)acetate for use in military and civilian medicine

    by D. L. Usenko, B. O. Varynskyi, O. I. Panasenko, L. P. Morozova, O. P. Shmatenko, A. M. Solomennyi

    Introduction. Chromatographic methods are often used in the study of pharmacokinetic parameters. Thus, the aim of the study was to investigate the pharmacokinetic parameters and metabolism of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate (ASP) as a potential active pharmaceutical ingredient with high rates of proven acto- and stress-protective effects, which can be recommended for use in military and civilian medicine. The aim of the study is to investigate the pharmacokinetic parameters and metabolism of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate (ASP) in the blood serum of rats by intragastric administration. Materials and methods. Blood sampling of experimental animals was carried out within 24 hours with intervals of 0.25, 0.75, 2.5, 7.5, 13.5 and 24 hours. Approval of the ethics committee № 6 of 08.06.2021. The obtained plasma was used to determine the concentration of ASP (chromatographically) and identify possible metabolites (mass spectrometrically). To evaluate the pharmacokinetic properties of ASP, the following data were calculated: area under the pharmacokinetic curve "concentration-time" (AUC), total clearance (cl), the constant elimination (Kel), volume (Vd), period elimination half-life (T1/2). Results. The analysis of the main pharmacokinetic parameters of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate (ASP) by intragastric introduction to rats was held. For oral use AUC is 3.7088 μgh/ml. The half-life (T1/2) is 6.06 hours. The following possible metabolic products were predicted for phase II biotransformation. This is a reaction of O-glucuronation of an aliphatic acid, formation of a thioester through S-methylation, and possible formation of a glycine conjugate. And also carnitine conjugation (based on a collection of enzymes). Analysis of the pseudomolecular ion peak shows the possible formation of a glycine conjugate corresponding to the structure predicted in BioTransformer. The presence of O-glucuronide as a metabolite was confirmed by PLS DA VIP score and t-test analysis. Conclusions. As a result, the main pharmacokinetic parameters (AUC, cl, Kel, Vd, T1/2) and metabolism (formation of thioether, formation of conjugate of glycine and O-glucuronide) of sodium 2-((4-amino-5-(thiophene)-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate (ASP) in the blood serum of rats was studied.


  • Open Access

    Impact of protein and carnitine consuption on outcomes of care development of full-term newborns with critical perinatal diseases

    by I.O. Anikin, B.O. Varynskyi, L.S. Stryzhak, L.N. Serhieieva, V.I. Snisar

    There were studied results of the impact of increased consumption of proteins and L-carnitine in the nutrition program of full-term newborns with perinatal diseases on the results of physical development and inpatient treatment features. The purpose of the work was to study the correlations between short-term higher consumption of protein and carnitine by full-term newborns and the results of their physical development, the duration of hospital care development. The vital signs of 59 full-term newborns were studied in a randomized controlled trial in the period 2017-2020. The main critical disease of the perinatal period in newborns of both groups was found to be hypoxic-ischemic encephalopathy of a moderate degree in 86.7% and 86.2%, without a statistically significant difference. One group (n=30) received nutrition with mother's milk or formula, the second group (n=29) received similar nutrition with fortification with a protein and L-carnitine supplement during the hospital stay. At the beginning and at the end of the treatment, physical development of the newborns was studied and correlations between the obtained data were investigated. Newborns of both groups did not differ in characteristics at the beginning of the study. The proportions of the newborns' weight corresponded to the limits of the 50% percentile. The group with increased consumption of protein and carnitine, fortification group (FG) demonstrated better indicators of physical development, they regained body mass faster. Body mass of the newborns of the fortification group goup was 3966.9±439.1 g, compared to the standard nutrition (SN) group, with indicators being 3554.6±452.3 g, at p=0.003. The rate of increase in body length in FG was twice that of the SN group. Consumption of a larger dose of protein was accompanied by a shorter stay in the intensive care unit – 10.0 (8.0; 12.0) days versus 12.0 (11.0; 16.0) days, with U=235.0; p=0.002; earlier discharge from the hospital – 21.0 (19.0; 27.0) days versus 26.5 (22.0; 31.0) days, with U=267.0, p=0.01. Carnitine supplementation in the FG group led to an increase in the level of free carnitine in the blood plasma samples taken before the discharge from the hospital. The study of correlations revealed a positive correlation between the consumption of a full dose of proteins and the total increase in height (R=0.3, p<0.05), the increase in body weight (R=0.3, p<0.05). A negative correlation was found between the protein level and the duration of treatment in the hospital (R= -0.3, p<0.05). The level of free carnitine had a positive effect on the increase in body length (R=0.51, p<0.05), daily weight gain (R=0.3, p<0.05). A poor increase in body length was associated with a longer duration of respiratory support: the correlation had an inverse direction R= -0.4, p<0.05. Improving nutritional strategies has significant prospects for improving care development of full-term babies with critical perinatal states.

  • Open Access

    Determination of the isotonicity 1 % solution of sodium 2-((4-amino-5-thiophen-2-ylmethyl)-4H-1,2,4-triazole-3-yl)thio)acetate

    by D. L. Usenko, A. H. Kaplaushenko, B. O. Varynskyi

    The aim of the work is to justify the composition of a 1 % aqueous solution of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazole-3-yl)thio)acetate for parenteral use. Materials and methods. The osmolality study of a 1 % solution of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazole-3-yl)thio)acetate was conducted using the cryoscopic method according to the State Pharmacopoeia of Ukraine (2.2.35). The calculations were based on measuring the depression of the crystallization temperature of the 1 % solution of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazole-3-yl)thio)acetate, 0.9 % NaCl solution, and high-purity water (Q3). The measurements of crystallization temperature were performed using a Beckman TL-1 thermometer, which allows for research with high precision up to ± 0.005 °C, making it valuable and most effective for studying isotonic concentration. Results. Temperature measurements of the crystallization of a 1 % solution under investigation, a 0.9 % NaCl solution, and high-quality purified water were conducted. Calculations of isotonic concentration were performed based on the measurement results. Conclusions. Based on the obtained experimental data on the depression of the crystallization temperature and the calculations, the amount of sodium chloride necessary for the preparation of an isotonic 1 % aqueous solution of AFI sodium 2-((4-amino-5-thiophen-2-ylmethyl)-4H-1,2,4-triazole-3-yl)thio)acetate for parenteral use was established.


  • Open Access

    Determination of riboflavin in dragee “Revit” by HPLC

    by B. О. Varynskyi, M. Yu. Zeleniuk, A. H. Kaplaushenko, М. Ю. Зеленюк

    The aim of the work is development of express, selective, reproducible methods for the determination of riboflavin by HPLC in a multivitamin preparation, dragee “Revit”. Materials and methods. Degasser, binary pump, autosampler, thermostated column compartment, diode array detector. Chromatographic column Zorbax SB-C18, 30 mm × 4.6 mm, 1.8 µm. Samples were prepared using analytical electronic scales Kern ABT 100-5M, ultrasonic bath Ultrasonic XUBA 3, nylon ultrafilters 0.12 µm. Results. 0.1 % formic acid was selected as a buffer solution in the eluent. The maximum values of logD were observed at intervals for riboflavin at pH from 2 to 4. Therefore, the maximum retention of the riboflavin was observed when using the eluent, рН which corresponds to this interval. The pH value for 0.1 % formic acid solution was 2.7. Therefore, such a buffer was chosen by us as part of the eluent. Acetonitrile was selected as the organic modifier. The optimal content of the compound was observed at 10 % acetonitrile. Conclusions. The chromatographic behavior of riboflavin on the basis of chemical-analytical properties was studied. The optimal conditions for chromatographic determination were determined and a specific, express method for the determination of riboflavin in “Revit” dragee was developed. The technique on a real sample of “Revit” dragee was elaborated. The method was recommended for use in control and analytical and research laboratories.

  • Open Access

    ТЕРМОДИНАМІЧНА ХАРАКТЕРИСТИКА ОБЕРНЕНО-ФАЗОВОГО ХРОМАТОГРАФІЧНОГО УТРИМАННЯ МОРФОЛІНІЙ 2-((4-(2-МЕТОКСИФЕНІЛ)-5-(ПІРИДИНІЛ)-4H-1,2,4-ТРІАЗОЛ-3-ІЛ)ТІО) АЦЕТАТУ ТА ЙОГО ТЕХНОЛОГІЧНИХ ДОМІШОК

    by B. O. Varynskyi

    Мета роботи. Зробити термодинамічний опис перенесення морфоліній 2-((4- (2-метоксифеніл)-5-(піридин-4-іл)-4H-1,2,4-тріазол-3-іл)тіо) ацетату, піридин-4-карбогідразиду, 2-ізонікотиноїл-N-(2-метоксифеніл) гідразин-1-карботіоаміду і 4-(2-метоксифеніл)-5-(піридин-4-іл)-2,4-дигідро-3Н-1,2,4-тріазол-3-тіону з рухомої фази в стаціонарну. Матеріали і методи. Високоефективна рідинно-хроматографічна система Agilent 1260 Infinity (дегазатор, бінарний насос, автосамплер, термостат колонки, діодно-матричний детектор, програмне забезпечення OpenLAB CDS). Результати й обговорення. Для визначення термодинамічних параметрів було визначено коефіцієнт ємності в залежності від зміни абсолютної температури. За допомогою методу найменших квадратів розраховано рівняння лінійної залежності. Розраховано значення стандартної молярної ентальпії перенесення аналітів із рухомої в стаціонарну фазу. Ентальпії перенесення для більшості речовин є негативними, тобто процес адсорбції на обернено-фазовому сорбенті відбувається з виділенням теплоти, тобто є екзотермічним. Висновки. Визначено стандартні ентальпії перенесення аналітів із рухомої фази в стаціонарну фазу для морфоліній 2-((4-(2-метоксифеніл)-5-(піридиніл)-4H-1,2,4-тріазол-3-іл)тіо) ацетату, піридин-4-карбогідразиду, 2-ізонікотиноїл-N-(2-метоксифеніл) гидразин-1-карботіоамиду та 4-(2-метоксифеніл)-5-(піридиніл)-2,4-дигідро-3Н-1,2,4-тріазол-3-тіону. Усі сполуки, за винятком піридин-4-карбогідразиду, мають негативне значення ентальпії перенесення, що свідчить про переважний перехід цих аналітів із рухомої фази в стаціонарну.

  • Open Access

    Metabolism study of morpholinium 2- ((4- (2-methoxyphenyl)-5-(pyridin-4-yl) -4H-1,2,4-triazole-3-yl)thio) acetate

    by Borys Varynskyi, Andriy Kaplaushenko

    Aim. The purpose of this study is to reveal the determination of the structure of the main metabolite of morpholinium 2-(4-(2-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazole-3-yl)thio)acetate (an active pharmaceutical ingredient – API) by way of chromatography through mass spectrometry detection, utilizing the liquid chromatography system Agilent 1260 Infinity and mass spectrometry detector (single quadrupole detector Agilent 6120). In the work, the graph of the change in the area of the peak of the metabolite from time after the introduction of the API solution was constructed. Moreover, the charges on the atoms of 2-((4-(2-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio) acetate were calculated and the structure of the methyl derivative was proposed. We saw that the methylation of the active substance during metabolism formed a 5-((carboxymethyl)thio)-4-(2-methoxyphenyl)-1-methyl-3-(pyridin-4-yl)-4H-1,2,4-triazol-1-um cation through N-methyltransferase.


  • PIPERIDINIUM 2-((5-(FURAN-2-YL)-4-PHENYL-4H-1,2,4-TRIAZOL)-3-YL) ACETATE FORCED DEGRADATION STUDY

    by Borys Varynskyi

    O bjective : Aim of the research to make forced degradation study of piperidinium 2-((5- (furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl) acetate in active pharmaceutical ingredient (API) , 0.1% solution and 1% solution for injection. I nfluence of the sodium hydroxide, hydrochloride acid, 3% Н 2 О 2 , temperature, UV radiation on piperidine 2-((5-(furan-2-yl) -4-phenyl-4H-1,2,4-triazol-3-yl) acetate substance, 0.1% solution and 1% solution for injections was studied. Material and method: Agilent 1260 Infinity HPLC System. Agilent single-quadrupole mass spectrometer 6120 . Result and discussion: Dependence of the quantitative content of the piperidinium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl) acetate from exposition time was determined. The composition of impurities formed under the action of an oxidizer was established (3%Н 2 О 2 ). This is sulfoxide and sulfone corresponding to the API. The composition of impurities which were formed under the influence of UV radiation was proposed.

  • Open Access

    The Force Degradation Study of The Morpholinium 2-((4-(2-Methoxyphenyl)-5-(Pyridin-4-YL)-4H-1,2,4-Triazol-3-YL) Thio) Acetate

    by Borys Varynskyi, Andriy Kaplaushenko

    The Force Degradation Study of The Morpholinium 2-((4-(2-Methoxyphenyl)-5-(Pyridin-4-YL)-4H-1,2,4-Triazol-3-YL) Thio) Acetate


  • Open Access

    The development of HPLC-DAD method for determination of active pharmaceutical ingredient in the potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio) acetate substance

    by Roman Shcherbyna, Volodymyr Parchenko, Boris Varynskyi, Andriy Kaplaushenko

    Derivatives of 1,2,4-triazole are actively researched by scientists and synthetic pharmacologists. The last studies have shown that potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)acetate with low toxicity series exhibits antioxidant and hepatoprotective properties. Therefore, the purpose of this work was to develop a method for determining the API in the potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)acetate substance using the method of high-performance liquid chromatography with diode array detection (HPLC-DAD). As a result of this work, it is shown that the developed method is specific and meets the requirements of linearity, accuracy and precision. The results of determining the contents of the API in real samples indicate that the method can be proposed to control the quality of the potassium 2-((4-amino-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)acetate substance.


  • Open Access

    ELECTROSPRAY IONIZATION MASS SPECTROMETRY FRAGMENTATION PATHWAYS OF SALTS OF SOME 1,2,4-TRIAZOLYLTHIOACETATE ACIDS, THE ACTIVE PHARMACEUTICAL INGREDIENTS

    by Varynskyi Borys, Kaplaushenko Andriy, Parchenko Vladymyr

    Objective: The goal of this research was to study fragmentation pathways of series salts of 1,2,4-triazolylthioacetate acids. Methods: The study was done in the Electrospray ionization source with single quadrupole mass spectrometer Agilent 6120 after elution through column Zorbax SB-C18, 30 mm × 4.6 mm, 1.8 μm at Agilent 1260 infinity high-performance liquid chromatography system. The series salts of 1,2,4-triazolylthioacetate acids were studied. These salts are active pharmaceutical ingredients of potential or registered pharmaceutical formulations. Results: The mass spectra of corresponding compounds have analyzed. The fragmentation patterns of these compounds decay have proposed. Conclusions: Studying the fragmentation of the indicated substances can be used for detecting the mentioned substances, as well as for confirming the structure of new compounds with the mass spectrum based on the patterns described above.